Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 19 Oct 2026 for Enliven Therapeutics, Inc., €499k.
Insider track record
Disclosed buys
0
Disclosed sells
0
Signal history
No signal scores available.
Collins Helen Louise: trading record in brief
All filings by Collins Helen Louise on record concern Enliven Therapeutics, Inc. We count 2 filings; the first trade dates from 17 July 2026 and the latest from 19 October 2026.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
On 19 October 2026 came the latest disclosure, a transaction for €499k in Enliven Therapeutics, Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Collins Helen Louise
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations2 total
15,000 shares@ US$37.32CommonSEC144:0001974158-26-000109
15,000 shares@ US$50.860.023% mcap34.4% of flowCommonSEC144:0001974158-26-000084
2 of 2 declarations
